Media and Communications

News

2012 News Releases

Tuesday, December 18, 2012
Teva Calls 1.700% Senior Notes Due 2014 for Redemption

- Closes $2 Billion Senior Note Offering - JERUSALEM--(BUSINESS WIRE)--Dec. 18, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that its finance subsidiary Teva Pharmaceutical Finance IV, LLC has called for redemption its $1 billion outstanding principal amount of 1.700% senior notes due 2014 (CUSIP No. 88166H AA5). The redemption is being funded with proceeds from Teva’s offering of $2 billion principal amount of senior notes, which priced on December 13, 2012 and closed earlier today. T Read More »

Tuesday, December 18, 2012
Teva Signs New $3.0 Billion Syndicated Revolving Credit Facility

New Facility to Replace Existing $2.5 Billion Facility Secures Teva's Liquidity through Revolving Credit Lines JERUSALEM--(BUSINESS WIRE)--Dec. 18, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new five-year, $3.0 billion unsecured revolving credit facility, which replaces its existing $2.5 billion credit facility. “By signing this new revolving credit facility, with its increased size and extended term, we took another step on our recently announced new Read More »

Sunday, December 16, 2012
Teva Enters Agreement with Handok to Establish Business Venture with Significant Presence in Korean Pharmaceutical Market

- First commercial deal for Teva in East Asian territory outside Japan -- Pharmaceutical market in South Korea worth USD 14 billion – JERUSALEM & SEOUL, Korea--(BUSINESS WIRE)--Dec. 16, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Handok Pharmaceuticals Co., Ltd. (KRX: 002390) announced today their agreement to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately USD 14 billion. Under the terms of the agreement, Read More »

Thursday, December 13, 2012
Teva Receives A- Rating from Fitch Ratings with a Stable Outlook

JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2012-- Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that Fitch Ratings have assigned to it an initial long term issuer rating of A-, with a stable outlook. The credit rating agency said that the rating reflects Teva’s strategic position as the world's largest generic drug manufacturer, financial discipline, strong cash flow and liquidity, and capital deployment toward debt reduction. “Our decision to obtain a credit rating from Fitch further supports our Read More »

Thursday, December 13, 2012
Teva Announces Pricing of $2.0 Billion of Senior Notes

- Proceeds to be used for repayment of existing debt - JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2012-- Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that it successfully priced a debt offering by its special purpose finance subsidiaries, consisting of two tranches: $700,000,000 of 2.250% fixed rate senior notes maturing in March 2020 issued by Teva Pharmaceutical Finance IV, LLC; and $1,300,000,000 of 2.950% fixed rate senior notes maturing in December 2022 issued by Teva Pharmaceutical Finance Company BV The notes will be sold at a price of $999.55 and $998.02 per Read More »

Tuesday, December 11, 2012
Teva and Xenon Announce Teva’s World Wide License of Xenon’s Pain Drug XEN402

XEN402 is a Strategic Fit for Teva’s Commercial, R&D and Technology focus in CNS and Pain JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)--Dec. 11, 2012-- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that they have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a variety of painful disorders. This product specifically targets sodium channels which are abundantly found in Read More »

Thursday, December 06, 2012
Teva Invites the Public to Listen to Its 2012 Investor Meeting Webcast

JERUSALEM--(BUSINESS WIRE)--Dec. 6, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) invites investors and the general public to listen to a live audio webcast of its 2012 Investor Meeting on Tuesday, December 11, 2012 at 12:00 p.m. ET.     What: Teva’s 2012 Investor Meeting Read More »

Friday, November 30, 2012
Teva Provides 2013 Non-GAAP Financial Outlook

2013 Non-GAAP Diluted EPS of $4.85 to $5.15 JERUSALEM--(BUSINESS WIRE)--Nov. 30, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2013. Financial Targets: Total net revenues of between $19.5-$20.5 billion, consisting of:   Region   Net Revenues United States   $10.0 to $10.6B Europe   $5.5 to $6.1B Rest of World   $3.7 to $4.3B Total net revenues include the following major business lines: Generic medicines (including API) net reve Read More »

Thursday, November 29, 2012
Teva to Host Conference Call and Webcast on November 30, 2012

JERUSALEM--(BUSINESS WIRE)--Nov. 29, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will host a conference call and live webcast on Friday, November 30, 2012 at 8:00 a.m. ET to communicate its 2013 business outlook. A Question & Answer session will follow. A live webcast of the call will be available on Teva's website at: http://www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. The call can also be accessed by calling (at least 10 minutes before the scheduled start time) 1 Read More »

Monday, November 26, 2012
​Mr. Abraham (Barry) Cohen, a member of Teva's board of directors, passed away on November 22, 2012

​Teva Pharmaceutical Industries Ltd. mourns the passing of Mr. Abraham (Barry) Cohen, a longstanding member of the Board of Directors, who greatly contributed to the development of Teva over the past 20 years.Mr. Cohen had been a director of Teva since 1992. Over the many years during which he played an active role in the Board of Directors, Mr. Cohen assisted in implementing processes and strategies that transformed Teva into a leading global pharmaceutical company. His deep understanding of and vast experience in the pharmaceutical industry were invaluable to the Board of Directors. From 19 Read More »

​​​